EA201491165A1 - Вагинальное кольцо, содержащее dhea или сульфат dhea и возможно агент, модулирующий высвобождение активного ингредиента, полезное для увеличения овариального резерва у женщин и для облегчения симптомов, связанных с менопаузой - Google Patents

Вагинальное кольцо, содержащее dhea или сульфат dhea и возможно агент, модулирующий высвобождение активного ингредиента, полезное для увеличения овариального резерва у женщин и для облегчения симптомов, связанных с менопаузой

Info

Publication number
EA201491165A1
EA201491165A1 EA201491165A EA201491165A EA201491165A1 EA 201491165 A1 EA201491165 A1 EA 201491165A1 EA 201491165 A EA201491165 A EA 201491165A EA 201491165 A EA201491165 A EA 201491165A EA 201491165 A1 EA201491165 A1 EA 201491165A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mans
dhea
man
active ingredient
women
Prior art date
Application number
EA201491165A
Other languages
English (en)
Other versions
EA027633B1 (ru
Inventor
Франс Ариэль Фуэнтес Гарсия
Шу-Чень Чень
Марианела дель Кармен Бельтран Апабласа
Original Assignee
Универсидад Де Чиле
Лабораториос Андромако С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Универсидад Де Чиле, Лабораториос Андромако С.А. filed Critical Универсидад Де Чиле
Publication of EA201491165A1 publication Critical patent/EA201491165A1/ru
Publication of EA027633B1 publication Critical patent/EA027633B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Вагинальное кольцо с длительным высвобождением, содержащее дегидроэпиандростерон (DHEA), сульфат дегидроэпиандростерона (DHEA-S) или его фармацевтически приемлемую соль в качестве активного агента и возможно агент, модулирующий высвобождение активного ингредиента, где количество активного ингредиента составляет от 1 до 32 мас.% относительно общей массы композиции, и модулятор выбран из поливинилпирролидона K-30, лактозы, микрокристаллической целлюлозы и лаурилсульфата натрия. Вагинальное кольцо по настоящему изобретению может быть использовано для увеличения овариального резерва у женщин, для применения в качестве лекарственного средства во вспомогательных репродуктивных программах и для облегчения симптомов, связанных с менопаузой, таких как симптомы атрофии вульвы и влагалища, и половой дисфункции у женщин в постменопаузе.
EA201491165A 2011-12-29 2011-12-29 Вагинальное кольцо, содержащее dhea или сульфат dhea и возможно агент, модулирующий высвобождение активного ингредиента, полезное для увеличения овариального резерва у женщин и для облегчения симптомов, связанных с менопаузой EA027633B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/056023 WO2013098592A1 (es) 2011-12-29 2011-12-29 Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia

Publications (2)

Publication Number Publication Date
EA201491165A1 true EA201491165A1 (ru) 2014-12-30
EA027633B1 EA027633B1 (ru) 2017-08-31

Family

ID=48696405

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491165A EA027633B1 (ru) 2011-12-29 2011-12-29 Вагинальное кольцо, содержащее dhea или сульфат dhea и возможно агент, модулирующий высвобождение активного ингредиента, полезное для увеличения овариального резерва у женщин и для облегчения симптомов, связанных с менопаузой

Country Status (12)

Country Link
US (1) US9066956B2 (ru)
EP (1) EP2799042A4 (ru)
JP (1) JP5887424B2 (ru)
KR (1) KR101622861B1 (ru)
CN (1) CN104271084B (ru)
BR (1) BR112014014308A2 (ru)
CA (1) CA2860133C (ru)
CR (1) CR20140270A (ru)
EA (1) EA027633B1 (ru)
MX (1) MX350336B (ru)
NI (1) NI201400067A (ru)
WO (1) WO2013098592A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3272333A1 (en) 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d
CN108537785B (zh) * 2018-04-04 2021-04-30 北京大学人民医院 一种子宫超声微蠕动视频处理方法
US10918649B2 (en) * 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
WO2021111385A2 (en) 2019-12-06 2021-06-10 Prathima Chowdary Sustained release estrogen vaginal ring pessary for treatment of atrophy, cystitis and uterovaginal prolapse

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
ATE275957T1 (de) 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
ES2098193B1 (es) 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
WO1999021562A1 (en) 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
WO2002076426A2 (en) 2001-03-27 2002-10-03 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
EP1350541A1 (de) 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
US8501718B2 (en) 2005-11-08 2013-08-06 American Infertility Of New York Androgen treatment in females
US8501719B2 (en) 2005-11-08 2013-08-06 American Infertility Of New York Androgen treatment in females
US9375436B2 (en) 2004-10-26 2016-06-28 Norbert Gleicher Androgen treatment in females
US7615544B2 (en) 2004-10-26 2009-11-10 American Infertility Of New York Method of improving cumulative embryo score and quantity of fertilized oocytes, increasing euploidy rate and of normalizing ovarian function using an androgen such as dehydroepiandrosterone
US8067400B2 (en) 2004-10-26 2011-11-29 American Infertility Of New York Androgen treatment in females
US20060089308A1 (en) 2004-10-26 2006-04-27 American Infertility Of New York Method of improving ovulation induction using an androgen such as dehydroepiandrosterone
EP1890704A1 (en) * 2005-12-16 2008-02-27 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
SG195525A1 (en) * 2007-06-26 2013-12-30 Warner Chilcott Co Llc Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
NI201400067A (es) 2016-02-15
CR20140270A (es) 2014-10-31
BR112014014308A2 (pt) 2017-06-13
US9066956B2 (en) 2015-06-30
KR20140109987A (ko) 2014-09-16
EP2799042A1 (en) 2014-11-05
MX350336B (es) 2017-09-04
US20150004214A1 (en) 2015-01-01
CN104271084A (zh) 2015-01-07
CA2860133C (en) 2016-10-11
MX2014007957A (es) 2015-11-06
JP2015506933A (ja) 2015-03-05
WO2013098592A1 (es) 2013-07-04
KR101622861B1 (ko) 2016-05-19
EA027633B1 (ru) 2017-08-31
EP2799042A4 (en) 2015-02-11
CN104271084B (zh) 2017-03-01
CA2860133A1 (en) 2013-07-04
JP5887424B2 (ja) 2016-03-16

Similar Documents

Publication Publication Date Title
EA201491165A1 (ru) Вагинальное кольцо, содержащее dhea или сульфат dhea и возможно агент, модулирующий высвобождение активного ингредиента, полезное для увеличения овариального резерва у женщин и для облегчения симптомов, связанных с менопаузой
PE20130524A1 (es) Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
BR112013024558A2 (pt) pessários de uso único
HRP20192026T4 (hr) Formulacija tableta od neratinib maleata
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
NZ596844A (en) Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
AR081670A1 (es) Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
JP2011527709A5 (ru)
CL2011002847A1 (es) Uso de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal farmaceuticamente aceptable del mismo y un inhibidor de acetilcolinesterasa para preparar un medicamento util para mejorar la cognicion.
Sato et al. Interactions of vasopressin, prostaglandins, and cAMP in rat renal papillary collecting tubule cells in culture
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
JP2018527305A5 (ru)
HRP20230762T1 (hr) Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
PL1879572T3 (pl) Zastosowanie antagonistów oksytocyny i/lub wazopresyny we wspomaganym rozrodzie
AR088704A1 (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia
ECSP14008170A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
PH12015502326A1 (en) Progesterone receptor antagonist dosage form
DOP2014000143A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
CO7151514A2 (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia.
GT201400124A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
PE20142116A1 (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU